Acadia Pharmaceuticals | ACAD - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Cara Therapeutics USD 5.94M 983K 2025-09
Corcept Therapeutics USD 197.64M 219K 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Incyte USD 1.12B 3.53B 2025-12
J&J USD 18.97B 2.38B 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Prothena USD 27.23M 14.95M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12